Archives de l’auteur : Marianne Duparc
Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033
Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 Phase 1 study to evaluate safety and immunogenicity of sarbecovirus (coronavirus) vaccine candidate, OVX033, at ascending dose levels The trial will enroll 48 participants in France Lyon, France – February 15, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against …
Osivax Appoints Dr. Nicola Groth as Chief Medical Officer
Osivax Appoints Dr. Nicola Groth as Chief Medical Officer Lyon, France – January 25, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer. She brings over 25 years of experience …
Continuer la lecture « Osivax Appoints Dr. Nicola Groth as Chief Medical Officer »
Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836
Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 Grant to support preclinical evaluation of OVX836 in providing protection against pandemic influenza strains OVX836 has already been evaluated in several Phase 2 clinical trials against seasonal influenza with initial signals of broad-spectrum protection Lyon, France – December 5, 2023 …
Immunotherapies & Innovation for Infectious Diseases (I4ID) 2023
Lyon – Oral Presentation and Poster Florence Nicolas, Chief Development Officer and co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled « Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate ». Charlotte Primard, Preclinical Project Manager at Osivax, to present a poster entitled « Cross-reactivity of the …
Continuer la lecture « Immunotherapies & Innovation for Infectious Diseases (I4ID) 2023 »
World Congress Vaccine Europe 2023
Barcelona – PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate ”.
IDWeek 2023
Boston, MA – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a poster.
17th Vaccine Congress
Glasgow – PostersAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 and additional data on the cross-reactivity of the immune responses as part of two posters.
9th ESWI 2023
Valencia – PostersDelphine Guyon-Gellin, Chief Business Development Officer of Osivax, to provide a clinical update on OVX836 as part of a poster entitled « Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical Trial ». Florence Nicolas, Chief Development Officer and Co-founder of Osivax, to provide additional data …
